Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer

OBJECTIVE: To compare the efficacies of cefepime and ceftazidime as empiric therapy during the management of fever in cancer patients with chemotherapy-induced neutropenia. METHODS: A prospective, double-blind, randomized study of cefepime 2 g every eight hours and ceftazidime 2 g every eight hours was performed in 276 adult neutropenic (absolute neutrophil count < 500/mm3) cancer patients with fever. RESULTS: Median duration of neutropenia was five days. Sixty-one percent (n = 188) of the patients were evaluable. Treatment was successful in 57% (58/101) of cefepime-treated patients and 60% (52/87) of ceftazidime-treated patients (95% CI -18 to 12; p = 0.77). Bacteremic clearance occurred in 71% (12/17) of cefepime-treated patients and 40% (6/15) of ceftazidime-treated patients (p = 0.3). Both drugs were well tolerated. CONCLUSIONS: Cefepime appears to be as effective as ceftazidime in the initial treatment of febrile episodes in adult cancer patients with chemotherapy-associated neutropenia of modest duration.

This article has been cited by other articles:

				M. Paul, D. Yahav, A. Fraser, and L. Leibovici Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials J. Antimicrob. Chemother., February 1, 2006; 57(2): 176 - 189. [Abstract] [Full Text] [PDF]

				M. A. Sanz, J. Lopez, J. J. Lahuerta, M. Rovira, M. Batlle, C. Perez, L. Vazquez, A. Julia, J. Palau, M. Gutierrez, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial J. Antimicrob. Chemother., July 1, 2002; 50(1): 79 - 88. [Abstract] [Full Text] [PDF]